Cellyan Biotechnology Co., Ltd (HKPD)

NASDAQ: HKPD · USD

$1.87

-0.07 (-3.6%)· Recorded snapshot

Market cap	2.2M
Revenue (ttm)	13.4M
Net income (ttm)	-1.1M
EPS (ttm)	-$1.39
Shares out	1.2M
Volume	11,927

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 13.4M
Net income (ttm): -1.1M
EPS (ttm): -$1.39
Market cap: 2.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 20:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-15.6

P25 n/aP50 n/aP75 n/a

ROIC-9.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All HKPD indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002007702
Company name	Cellyan Biotechnology Co., Ltd
Country	Hong Kong
Country code	US
CUSIP number	G6365B112
Earnings date	2026-08-07
Earnings time	amc
Employees	11
Employees change	-16
Employees growth	-59.26%
Enterprise value	$3.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-03-31
First seen	2026-05-09
Fiscal year end	March
Founded	2016
Industry	Medical Distribution
IPO date	2025-01-15
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG6365B1124
Last 10-K release date	2026-08-07
Last earnings date	2026-08-07
Last refreshed	2026-11-04
Last stock split date	2026-10-26
Last stock split type	Reverse
Market cap	$2.2M
Market cap category	Nano-Cap
Next earnings date	2027-02-23
Options	No
Price	$1.87
Price currency	USD
Sector	Healthcare
SIC code	5122
Stock price date	2026-11-04
Symbol	HKPD
Website	https://www.9zt.hk

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-74.31%
EV/Sales	0.25x
FCF / EV yield	-23.74%
FCF yield	-34.53%
Industry forward P/E	19.77x
Industry P/E	28.33x
P/B ratio	0.24x
P/S ratio	0.17x
Price / tangible book value	0.24x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-7.48%
EBITDA margin	-6.84%
Gross margin	10.32%
Operating margin	-7.48%
Pretax margin	-8.4%
Profit margin	-8.46%
Profit per employee	$-103,269
Revenue per employee	$1.2M
ROA	-5.64%
ROCE	-10.42%
ROE	-15.59%
ROIC	-9.46%
Tax / revenue	0.06%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Gross profit growth	-42.6%
Gross profit growth (Q)	-79.5%
Net income growth years	0
Revenue growth	-33.87%
Revenue growth (Q)	-31.73%
Revenue growth (QoQ)	-11.78%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-35,470
Depreciation and amortization	$86,536
EBIT	$-1M
EBITDA	$-918,373
EPS	$-1.39
FCF per share	$-0.67
Financing cash flow	$-630,225
Free cash flow	$-787,072
Gross profit	$1.4M
Income taxes	$7,666
Investing cash flow	$857,457
Net borrowing	$-630,225
Net cash flow	$-527,280
Net income	$-1.1M
Operating income	$-1M
Revenue	$13.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.89
Book value per share	$8.16
Debt / equity	0.13
Interest coverage	-7.51
Long-term assets	$510,771
Long-term liabilities	$65,275
Net cash (debt)	$-1M
Net cash / market cap	-45.46%
Net debt / equity	0.11
Piotroski F-Score	2
Property, plant and equipment	$434,128
Shareholders' equity	$9.6M
Tangible book value	$9.5M
Tangible book value per share	$8.09
Total assets	$12.8M
Total cash	$221,841
Total debt	$1.3M
Total liabilities	$3.3M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.21
Current assets	$12.3M
Current liabilities	$3.2M
Current ratio	3.86
Inventory turnover	26.19
Net working capital	$10.1M
Quick ratio	1.69
Working capital	$9.1M
Working capital turnover	1.95

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-60.21%
Dividend yield	0%
Shareholder yield	-60.21%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$7.48
1D price change	-3.61%
1M price change	-14.16%
1M total return	-14.16%
1W price change	-13.76%
1W total return	-13.76%
1Y price change	-92.54%
1Y return CAGR	-92.55%
1Y total return	-92.54%
20-day SMA	$2.10
200-day SMA	$9.14
3M price change	-77.05%
3M total return	-77.05%
50-day SMA	$2.69
50-day SMA vs 200-day SMA	50under200
52-week high	$29.00
52-week high date	2025-11-20
52-week low	$1.63
52-week low date	2026-10-21
6M price change	-86.28%
6M total return	-86.28%
All-time high	$75.80
All-time high date	2025-01-15
All-time low	$1.63
All-time low date	2026-10-21
Average true range (ATR)	$0.30
Average volume	49K
Beta (1Y)	1.37
Beta (2Y)	1.28
Change from 52-week high	-93.55%
Change from 52-week low	14.87%
Change from all-time high	-97.52%
Change from all-time low	15.48%
Change from open	-6.5%
Day's gap	3.09%
Dollar volume	$22,303
High price	$2.05
Low price	$1.85
Monthly RSI	20.95
Open price	$2.00
Position in 52-week range	9.8%
Premarket change	2.06%
Premarket close	$1.94
Premarket price	$1.98
Premarket volume	307
Previous close	$1.94
Price vs 150-day SMA	-74.86%
Price vs 20-day SMA	-10.31%
Price vs 200-day SMA	-79.43%
Price vs 50-day SMA	-30.06%
Relative volume	0.24
Return from IPO open	-97.23%
Return from IPO price	-51.5%
RSI	35.51
Sharpe ratio	-1.92
Sortino ratio	-2.31
Volume	11.9K
Weekly RSI	23.96
YTD price change	-88.6%
YTD total return	-88.6%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Shares change (QoQ)	97.27%
Shares change (YoY)	60.21%
Shares outstanding	1.2M
Short % of shares	16.66%
Short ratio	0.2 days

Deeper analysis on HKPD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this HKPD report

Is a complete HKPD research report available?

No complete published report is available for Cellyan Biotechnology Co., Ltd (HKPD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cellyan Biotechnology Co., Ltd (HKPD)

Price

Financial snapshot

Fair-value bridge

Latest news · HKPD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All HKPD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on HKPD

Frequently asked questions